Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.

Abstract excerpt

OBJECTIVE: This study evaluated the relationship between the cytochrome P450 (CYP) 2C19 genotype and the antiplatelet effect of clopidogrel therapy and investigated whether genotyping can predict the risk of ischemic events after endovascular treatment (ET) of lower extremity peripheral arterial disease. METHODS: From January 2011 to July 2012, 120 consecutive patients with arteriosclerosis obliterans...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clopidogrel
• Share to Cytochrome P-450 CYP2C19